VACCINE TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION

Project: Research project

Description

DESCRIPTION: Hepatitis B virus
(HBV) is a hepatotropic virus that is a major public health concern
worldwide. While a recombinant surface antigen vaccine is available,
there is no effective treatment for the millions of individuals who are
chronically infected. The objective of this proposal is to develop
peptide therapeutics that will generate cytotoxic T lymphocytes (CTL) in
vivo and may ameliorate chronic HBV infections. These molecules may also
be useful as prophylactic vaccines. This study aims to 1. define the
9-10 amino acids that constitute the core CTL epitopes; 2. modify these
peptides to enhance their stability, facilitate uptake into antigen
presenting cells and to enhance immunogenicity by adding helper epitopes;
3. to determine if these peptides can generate CTL's in vivo (in HLA-A2
transgenic mice).
StatusFinished
Effective start/end date4/1/924/30/97

Funding

  • National Institutes of Health: $375,845.00

Fingerprint

Cytotoxic T-Lymphocytes
Hepatitis B virus
Vaccines
T-Lymphocyte Epitopes
Chronic Hepatitis B
Virus Diseases
Surface Antigens
Infection
Epitopes
Public Health
Viruses
Amino Acids
Peptides
Therapeutics

ASJC

  • Medicine(all)
  • Immunology and Microbiology(all)